|
May 25, 2012
|
| 11:13 EDT |  | PFE |
| theflyonthewall.com: | Chairman: Elan may get offer if Alzheimer drug data positive, Reuters says | | Elan's (ELN) chairman Bob Ingram said yesterday it was possible that the company could receive a takeover offer if data on an bapineuzumab, an experimental Alzheimer's drug it has a 25% economic interest in, is positive, reported Reuters. "If an offer comes in we can't ignore it, but it is not our strategy to sell the company," Ingram says. The drug is being developed by Pfizer (PFE) and Johnson and Johnson (JNJ), Reuters noted. Reference Link :theflyonthewall.com |
|
| 11:09 EDT |  | PFE |
|
| 09:14 EDT |  | PFE |
| theflyonthewall.com: | Pfizer's Axitinib receives positive opinion from CHMP | | Pfizer announced that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union for the treatment of adult patients with advanced renal cell carcinoma, a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine. The CHMP's positive opinion will be reviewed by the European Commission, which has the authority to approve medicines for the EU. Pfizer anticipates a decision from the Commission in the coming months. :theflyonthewall.com |
|
|
May 24, 2012
|
| 18:10 EDT | | PFE |
| theflyonthewall.com: | FDA committee finds Pfizer's clinical data supports effectiveness of novel drug |
 Subscribe for More Information :theflyonthewall.com |
|
| 07:38 EDT |  | PFE |
|
| 07:13 EDT | | PFE |
| theflyonthewall.com: | J&J's Xarelto likely delayed 3-12 months, not dead, says Leerink | | Leerink believes the FDA panel vote against approval of Johnson & Johnson's (JNJ) and Bayer's (BAYRY) Xarelto for the prevention of CV events in patients with a recent acute coronary syndrome will likely delay approval by 3-12 months, not kill the drug for this indication. The firm believes Bristol-Myers' (BMY) and Pfizer's (PFE) Eliquis could benefit slightly from a Xarelto delay. :theflyonthewall.com |
|
|
May 23, 2012
|
| 07:51 EDT | | PFE |
|
| 07:10 EDT | | PFE |
| theflyonthewall.com: | FTC, Senate probing blocking of generic drug companies, Washington Post says | | The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com |
|
|
May 21, 2012
|
| 07:38 EDT | | PFE |
|
|
May 18, 2012
|
| 14:04 EDT | | PFE |
| theflyonthewall.com: | Pfizer recalls Advil medicine, WSJ reports | | Pfizer (PFE) recently recalled more than 650,000 bottles of its Advil pain relief medicine because the pills could emit a strong odor, according to The Wall Street Journal. Reference Link :theflyonthewall.com |
|
| 08:04 EDT | | PFE |
|
|
May 17, 2012
|
| 17:45 EDT | | PFE |
|
| 06:02 EDT | | PFE |
|
|
May 15, 2012
|
| 17:10 EDT | | PFE |
| theflyonthewall.com: | Pfizer reports positive results for Phase 3 Intorsect study evaluating Torisel | | Pfizer announced that the Phase 3 INTORSECT study, evaluating TORISEL in patients with advanced renal cell carcinoma whose disease had progressed on or after SUTENT therapy, did not meet the primary endpoint of prolonging progression free survival when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Adverse events in this study were consistent with the known safety profiles for both drugs. Full efficacy and safety data from this study will be presented at an upcoming major medical congress. :theflyonthewall.com |
|
| 10:09 EDT | | PFE |
|
| 09:37 EDT | | PFE |
|
| 07:24 EDT | | PFE |
|
| 06:10 EDT | | PFE |
|
|
May 14, 2012
|
| 08:05 EDT | | PFE |
|
